the downgrade specifically noted "risks to re-start" and "risk of going after a new ore body", and said shares could be revalued if and when start up is successful - implying what you suggest about asset write up , not sure how much they get back of the write down of $200mm . also of note, they dont include any value for El Quevar - if and when Argentina calms down, there is chance they do get a JV done to finance operations there, at which pt will be very hard not to assign value
fine. take in the cash. im ready for rebrand including new name.
they paid $4.4 mm, what do you think they could get for it ?
stock is cheap on all metrics, relative to revenues, earnings, cash flow. chart also looks like a cup and handle to me. bulletin board lets us buy this stock at a discount. good luck to all
Transgenomic Sells Rights to SURVEYOR Mutation Detection Technology and Assets to Integrated DNA Technologies, Inc.
Wed July 2, 2014 7:00 AM|Business Wire | About: TBIO
Selective Monetization of Research Market Assets Reflects Strategic Focus on Higher Growth Molecular Diagnostics and Personalized Medicine Sectors
OMAHA, Neb.--(BUSINESS WIRE)-- Transgenomic, Inc. (TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that it has entered into an agreement to sell to Integrated DNA Technologies, Inc. (IDT) the rights to Transgenomics SURVEYOR Nuclease technology and assets for a minimum of $4.25 million. SURVEYOR Mutation Detection Kits provide researchers with a simple, robust and versatile method to detect mutations and polymorphisms in DNA from a variety of organisms.
Under the terms of the agreement, IDT will make an upfront payment of $3.65 million and additional minimum payments of $0.6 million or more to Transgenomic during the first year of the agreement. Transgenomic will transfer rights to the SURVEYOR patents, license, technology, know-how and trademarks to IDT, as well as all inventory of the product. As part of the agreement, IDT will exclusively sublicense rights for all clinical and diagnostic applications of the SURVEYOR technology back to Transgenomic. Further terms of the agreement were not disclosed.
Paul Kinnon, President and Chief Executive Officer of Transgenomic, commented, The sale of SURVEYOR Nuclease technology to IDT for the non-core research market allows us to focus more of our resources on commercialization efforts in our Patient Testing, Biomarker Identification, and Genetic Assays and Platforms business units. By licensing back exclusive rights to clinical and diagnostic uses of the technology, we have ensured we will have continued access to SURVEYOR in high value clinical and ph
re pt 1 - agree still super vague strange wholesale market - good thing i think diamonds will be healthy market for next 5 years. re pt 3. i do no want them to begin cash return until spending cycle to build out their assets and enhance production is complete. next few years look very very good as capx trails off. re pt 4, i prefer less coverage - makes for better opportunity for investors at right time which i think is finally now. re pt 5 - they have done a lot so that we are now entering a strong period of growth, after which we again as you pint out have to worry about mine life again
I dont understand thumbs down either without a comment. I thought last eps report was good and points way to increased production with spending that wil tail off leading to significant free cash flow. while the business is difficult, I am constructive on diamond mining in a mining friendly jurisdiction
Agree. one must or should want to own fundamentally too. good news is here is in my view, fundamentals and valuation still very attractive where stock closed .....
the nonsense helps keep nice short interest, i dont mind, shares to be bought back later. agree re Beat Port - why not B to C like they suggest and perhaps streaming ?
US market critical agreed but they are not jus selling in Korea, they are selling in Europe. at least you know pretty quickly in a study here whether it works. i find its effectiveness on burns fascinating. am i nuts ?
Are you sure about that ? There are a plenty of famous and not famous investors who go where ever they find value whether in large cap or micro cap. its all about value. NHLD is not a stock for day traders as you cannot get in an out of it but you know this already.
this sounds interesting. can you please direct me to where I can read about this early stoppage. i dont see current news on it. but obviously I'm missing where to look
only positive thing i can write, is that i'm so incredibly annoyed with fact i hold these shares, that perhaps its finally the bottom
great comment. they help raise money for the small companies that actually will use the money mostly for cap x and hiring. playing a valuable role. and btw for the bears, one of most respected financial investors around , Mendon, has been adding to their significant holding. Hard for bears to attack Mendon as quality shareholder
I find it interesting that NHLD has settled with Iroquois and two principals from the fund are joining NHLD's board, and that NHLD is making room by having two existing board members depart. I feel this is good for shareholders